trial

A Clinical Trial of Lurasidone in Treatment of Schizophrenia

NCTId NCT02002832
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 388 (actual)
Sponsored by Marubeni Pharmaceuticals (Suzhou) Co., Ltd.
Primary completion 2015-04
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
388 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2013-12
Primary completion
2015-04
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
LurasidoneRisperidone

Sponsors

Marubeni Pharmaceuticals (Suzhou) Co., Ltd.Lead Sponsor

Investigators

1
Zhuoji CAI, MDPrincipal Investigator

Sites

15 total
Beijing, ChinaBeijing, ChinaBeijing, ChinaGuangzhou, ChinaBaoding, ChinaXinxiang, ChinaChangsha, ChinaChangsha, ChinaNanjing, ChinaWuxi, ChinaShanghai, ChinaXi’an, China

Linked catalysts

1
A Clinical Trial of Lurasidone in Treatment of Schizophrenia — primary completion2015-04

Facts & assertions

4 sourced
Enrollment
388
Phase
PHASE3
Primary Completion Date
2015-04
Status
COMPLETED
relationships
The graph out of here
drug
Lurasidone
drug
Risperidone
drug
lead_sponsor
Marubeni Pharmaceuticals (Suzhou) Co., Ltd.
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Zhuoji CAI, MD
person